Københavns Fondsbørs rises for the fourth day in a row

The market showed a small gain Thursday, and OMX Copenhagen 25 GI (OMXC25GI) ended the day at 1514 points, which is an increase of 0.38 percent. The index has now risen for the fourth day in a row.

67 shares were up and 64 were down, while 20 remained unchanged, and there was no trading in 11 shares.

Total value of the trading volume for shares and primary capital certificates Thursday was approximately 5.9 billion.

ISS (ISS) closed at 99.50 kroner after a loss of 2.78 percent. The stock therby broke below the 100 -mark for the first time since May 15. The stock has thereby closed down 13 out of the past 16 days and this past month the stock has lost as much as 19.24 percent. It does not look good technically either. The stock is trend wise negative in the medium term and a further decline is indicated.
Grønlandsbanken (GRLA) showed a small gain and ended the day at 615 kroner, which is an increase of 0.82 percent. This past week the stock has gained as much as 20.59 percent. Technically it also looks good. The stock is trend wise negative in the medium term, but has support at 550 kroner.
Tryg (TRYG) closed at 191 kroner after a steep drop of 4.60 percent. The stock has never lost more in one day since Jun 15, when it was down 8.53 percent.
SimCorp (SIM) increased slightly 1.10 percent and ended the day at 736 kroner. The stock has thereby closed up nine out of the past ten days. Technically it also looks good. The stock is trend wise positive in the medium term and a further increase is indicated.
ChemoMetec (CHEMM) moved horizontally and closed at 398 kroner (+0.38 percent). The stock has now risen for the seventh day in a row and this past week the stock has gained as much as 17.93 percent. Technically it also looks good. The stock is trend wise positive in the medium term, has support at 260 kroner and a further increase is indicated.

Most traded Thursday

Novo Nordisk B651.29
Vestas Wind Systems554.56
Ørsted506.97
Pandora479.54
Genmab389.68
 


Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer. The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.


Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer. The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.

Titlex

OK